145 related articles for article (PubMed ID: 25269558)
1. The molecular mechanisms of TRAIL resistance in cancer cells: help in designing new drugs.
Wang F; Lin J; Xu R
Curr Pharm Des; 2014; 20(42):6714-22. PubMed ID: 25269558
[TBL] [Abstract][Full Text] [Related]
2. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.
Dai X; Zhang J; Arfuso F; Chinnathambi A; Zayed ME; Alharbi SA; Kumar AP; Ahn KS; Sethi G
Exp Biol Med (Maywood); 2015 Jun; 240(6):760-73. PubMed ID: 25854879
[TBL] [Abstract][Full Text] [Related]
3. Spatial dynamics of TRAIL death receptors in cancer cells.
Twomey JD; Kim SR; Zhao L; Bozza WP; Zhang B
Drug Resist Updat; 2015 Mar; 19():13-21. PubMed ID: 25840763
[TBL] [Abstract][Full Text] [Related]
4. Fucoxanthin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Synergistically Promotes Apoptosis of Human Cervical Cancer Cells by Targeting PI3K/Akt/NF-κB Signaling Pathway.
Jin Y; Qiu S; Shao N; Zheng J
Med Sci Monit; 2018 Jan; 24():11-18. PubMed ID: 29291370
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of Fuligocandin B Derivatives with Activity for Overcoming TRAIL Resistance.
Arai MA; Masuda A; Suganami A; Tamura Y; Ishibashi M
Chem Pharm Bull (Tokyo); 2018; 66(8):810-817. PubMed ID: 30068801
[TBL] [Abstract][Full Text] [Related]
6. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
Festuccia C; Gravina GL; D'Alessandro AM; Millimaggi D; Di Rocco C; Dolo V; Ricevuto E; Vicentini C; Bologna M
Int J Oncol; 2008 Aug; 33(2):381-8. PubMed ID: 18636160
[TBL] [Abstract][Full Text] [Related]
7. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis.
Baritaki S; Militello L; Malaponte G; Spandidos DA; Salcedo M; Bonavida B
Int J Oncol; 2011 Jun; 38(6):1683-94. PubMed ID: 21455568
[TBL] [Abstract][Full Text] [Related]
8. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL).
Fulda S
Adv Exp Med Biol; 2014; 818():167-80. PubMed ID: 25001536
[TBL] [Abstract][Full Text] [Related]
9. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
10. Bio-active Natural Products with TRAIL-Resistance Overcoming Activity.
Ahmed F; Ishibashi M
Chem Pharm Bull (Tokyo); 2016; 64(2):119-27. PubMed ID: 26833440
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for nuclear factor kappaB in tumor necrosis factor-related apoptosis-inducing ligand resistance?
Plantivaux A; Szegezdi E; Samali A; Egan L
Ann N Y Acad Sci; 2009 Aug; 1171():38-49. PubMed ID: 19723036
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole.
Goda AE; Yoshida T; Horinaka M; Yasuda T; Shiraishi T; Wakada M; Sakai T
Oncogene; 2008 May; 27(24):3435-45. PubMed ID: 18193086
[TBL] [Abstract][Full Text] [Related]
13. From biochemical principles of apoptosis induction by TRAIL to application in tumour therapy.
Cordier SM; Papenfuss K; Walczak H
Results Probl Cell Differ; 2009; 49():115-43. PubMed ID: 19142621
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
Zhang L; Fang B
Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
[TBL] [Abstract][Full Text] [Related]
15. The three Rs along the TRAIL: resistance, re-sensitization and reactive oxygen species (ROS).
Mellier G; Pervaiz S
Free Radic Res; 2012 Aug; 46(8):996-1003. PubMed ID: 22559302
[TBL] [Abstract][Full Text] [Related]
16. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
Thorburn A; Behbakht K; Ford H
Drug Resist Updat; 2008; 11(1-2):17-24. PubMed ID: 18374623
[TBL] [Abstract][Full Text] [Related]
17. Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL).
Elmallah MI; Micheau O
Mar Drugs; 2015 Nov; 13(11):6884-909. PubMed ID: 26580630
[TBL] [Abstract][Full Text] [Related]
18. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation.
Tanaka H; Hoshikawa Y; Oh-hara T; Koike S; Naito M; Noda T; Arai H; Tsuruo T; Fujita N
Mol Cancer Res; 2009 Apr; 7(4):557-69. PubMed ID: 19372584
[TBL] [Abstract][Full Text] [Related]
19. Cytokines from the tumor microenvironment modulate sirtinol cytotoxicity in A549 lung carcinoma cells.
Pal S; Shankar BS; Sainis KB
Cytokine; 2013 Oct; 64(1):196-207. PubMed ID: 23972545
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition.
Morales JC; Ruiz-Magaña MJ; Ruiz-Ruiz C
Mol Immunol; 2007 Apr; 44(10):2587-97. PubMed ID: 17257681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
